Non-opioid treatment; terms; preferred drug lists; discretion; drug treatment; United States Food and Drug Administration; coverage; non-opioid drugs; reimbursement; effective date.

The definition of 'Non-opioid treatment' was updated to specifically include 'drug treatment' in the applicability section for clarity.

The requirement that insurers ensure non-opioid FDA-approved drugs are not disadvantaged on preferred drug lists was retained but reorganized for clarity.

The bill was reformatted from an 'Engrossed' version to a 'Proposed Committee Substitute' with updated committee amendment headers and page numbering.

The effective date of November 1, 2025 was retained in the new version.

Title changed from 'An Act relating to non-opioid treatment' to a bracketed summary format listing key topics.

Added 'Rosino of the Senate' as a co-sponsor alongside the House sponsor.

Page headers and footers were updated from 'Introduced' version to 'Engrossed' version with new page numbering.

Effective date section was moved to Section 2 and the House passage date was added.

Definition of 'Non-opioid treatment' was expanded to include FDA therapeutic equivalence evaluation requirements.

Section D was restructured to clarify that the coverage requirement applies to drugs reviewed and approved by a group insurance plan or insurer.

Changed the document title from 'PROPOSED OVERSIGHT COMMITTEE SUBSTITUTE' to 'COMMITTEE SUBSTITUTE' and updated the request number from 12857 to 12964 to reflect the committee's revised version.

Adjusted line numbers and page references throughout the document to align with the new committee substitute version.